Status:
RECRUITING
PRostate Cancer Plasma Integrative Multi-modal Evaluation
Lead Sponsor:
Santa Chiara Hospital
Collaborating Sponsors:
Università degli Studi di Trento
Conditions:
Metastatic Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The study aims to develop PRIME (PRostate cancer plasma Integrative Multi-modal Evaluation) liquid biopsy test and to implement its use to query prospectively collected samples in advanced prostate ca...
Eligibility Criteria
Inclusion
- Diagnosis of prostate cancer
- Eligible for prostate cancer pharmacological treatment
- Given consent to study participation
Exclusion
- \- Histological diagnosis other than prostate cancer
Key Trial Info
Start Date :
May 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06981377
Start Date
May 7 2019
End Date
January 31 2027
Last Update
May 20 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Romagnolo per lo Studio dei Tumori
Meldola, Forlì-Cesena, Italy, 47014
2
Azienda Ospedaliera San Luigi
Orbassano, Torino, Italy, 10043
3
Istituto Oncologico Veneto
Padua, Italy, 35128
4
Santa Chiara Hospital
Trento, Italy, 38122